Agios Pharmaceuticals (AGIO) Gross Profit (2017 - 2026)

Agios Pharmaceuticals (AGIO) has 9 years of Gross Profit data on file, last reported at $41.7 million in Q2 2026.

• Quarterly Gross Profit rose 288.25% year-over-year to $41.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $90.5 million (up 150.98% YoY) and the FY2025 annual result came in at $47.7 million, up 47.47% from the prior year.
• Gross Profit climbed to $41.7 million in Q2 2026, from $19.4 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $41.7 million in Q2 2026 to a low of $493000.0 in Q1 2022.
• A 5-year average of $9.9 million and a median of $7.3 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit jumped 925.35% — and 2025, when it grew 1.04%.
• Tracing AGIO's Gross Profit over 5 years: stood at $3.9 million in 2022, then soared by 67.23% to $6.5 million in 2023, then surged by 45.31% to $9.5 million in 2024, then soared by 91.0% to $18.1 million in 2025, then soared by 130.81% to $41.7 million in 2026.
• The last three Gross Profit figures came in at $41.7 million (Q2 2026), $19.4 million (Q1 2026), and $18.1 million (Q4 2025), per Business Quant data.